drugset / Trial / NCT02652754
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers
Phase 1
Completed
16 enrolled
Xequel Bio, Inc.
Medical University of South Carolina · collabSpartanburg Regional Healthcare System · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the systemic exposure of Granexin® gel after topical application to human subjects' diabetic foot ulcers.
Timeline
- Start
- 2015-09
- Primary completion
- 2017-12
- Completion
- 2018-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACT-1 PEPTIDE | Peptide | — | Topical |